Media Library

Acute lymphoblastic leukemia (ALL) is a cancer of the blood and lymphocytes, and is a common cancer diagnosis in children.

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphocytes.Leukemia, a cancer of the blood, begins when normal blood cells change and grow uncontrollably. Acute lymphocytic leukemia is a cancer of the lymphocytes, a type of white blood cell involved in the body’s immune system.

While there are many different sub-types of non-Hodgkin lymphoma (NHL), each are unique in how they present in patients and how they should be treated. Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing), complex and difficult- to-treat form of NHL. NHL refers to a group of cancers of the lymphatic system that develop from the lymphocytes, a type of white blood cell involved in the body’s immune system.

Migraine can have up to four distinct phases—premonitory (or prodrome), aura, headache and post-drome— and each of them has many potential symptoms.

Hospitalization provides an opportunity for physicians to optimize heart failure treatment to reduce the likelihood of hospital readmission and death, reduce the burden of hospitalizations, and improve outcomes for patients living with heart failure.

Novartis and AveXis combine, aiming to transform the care of SMA, the #1 genetic cause of infant mortality.

The factsheet “Strengthening our Global Health & Corporate Responsibility function” provides an overview of our Global Health & Corporate Responsibility governance, structure, strategic priorities and commitments.

The fact sheet “Building trust with society: our priorities” provides key highlights around 4 areas: pricing and access to medicines; global health challenges; ethical standards; and corporate responsibility.

The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

Since 2015, Novartis Access has worked to deliver treatments for chronic diseases in lower-income countries. Read our two-year report for an in-depth look at results, learnings and challenges on the ground so far. It includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

As a leading healthcare company, we have a responsibility to help people get access to the treatments they need, no matter where they live. Our CR Performance Report gives you all the facts on the progress we are making. It is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

10 years ago we launched the Healthy Family program, Novartis first social business model, to improve health via education, affordable products and health services. This report provides information on how the program has evolved since then. It includes external perspectives and country updates, showcasing the learnings and progress we have made over the years.